Nanobiotix S.A. (NBTX)
Nasdaq · Healthcare · Biotechnology
$25.10−2.52%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $1.3B
- 52-week range
- $14.78 – $57.14
- 52-week change
- +22.79%
- EPS (trailing)
- −$1.27
- Analyst rating
- 1.4 Strong buy
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Headquarters: Paris, France · 100 employees · nanobiotix.com